Edlaine Rijo Costa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Edlaine Rijo Costa has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Ribeiro Silva
Laboratório de Imunofarmacologia
1 shared publication Alessandra Silveira Ferreira
Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil
1 shared publication- Angela R. M. Kurz
Centenary Imaging and Sydney Cytometry at the Centenary Institute, The University of Sydney, Camperdown, Australia
1 shared publication Attila Mócsai
MTA-SE "Lendület" Inflammation Physiology Research Group, Department of Physiology, Semmelweis University, Budapest, Hungary
1 shared publicationBarbara Walzog
Walter Brendel Centre, Department of Cardiovascular Physiology and Pathophysiology, Klinikum der Universität, Ludwig Maximilians University München, Munich, Germany
1 shared publication- Cassiano Felippe Gonçalves-De-Albuquerque
Immunopharmacology Laboratory, Federal University of State of Rio de Janeiro
1 shared publication
Latest Publications
- 21 July 2022
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 43 (5) , 631-640
The effect of dietary fibers on the absorption of oral hypoglycemic drugs: a systematic review of controlled trials
- 21 July 2022
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 43 (5) , 631-640
The effect of dietary fibers on the absorption of oral hypoglycemic drugs: a systematic review of controlled trials
- 1 June 2020
- Published by Elsevier in Journal of Chromatography B
- Vol. 1146, 122127
Pretreatment and non-specific binding in ultrafiltration device: Impact on protease inhibitor quantification
- 1 June 2020
- Published by Elsevier in Journal of Chromatography B
- Vol. 1146, 122127
Pretreatment and non-specific binding in ultrafiltration device: Impact on protease inhibitor quantification
- Open Access
- 30 April 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 901
The Yin and Yang of Tyrosine Kinase Inhibition During Experimental Polymicrobial Sepsis
Neutrophils are the first cells of our immune system to arrive at the site of inflammation. They release cytokines, e.g., chemokines, to attract further immune cells, but also actively start to phagocytose and kill pathogens. In the case of sepsis, this tightly regulated host defense mechanism can become uncontrolled and hyperactive resulting in severe organ damage. Currently, no effective therapy is available to fight sepsis; therefore, novel treatment targets that could prevent excessive inflammatory responses are warranted. Src Family tyrosine Kinases (SFK), a group of tyrosine kinases, have been shown to play a major role in regulating immune cell recruitment and host defense. Leukocytes with SFK depletion display severe spreading and migration defects along with reduced cytokine production. Thus, we investigated the effects of dasatinib, a tyrosine kinase inhibitor, with a strong inhibitory capacity on SFKs during sterile inflammation and polymicrobial sepsis in mice. We found that dasatinib-treated mice displayed diminished leukocyte adhesion and extravasation in tumor necrosis factor-α-stimulated cremaster muscle venules in vivo. In polymicrobial sepsis, sepsis severity, organ damage, and clinical outcome improved in a dose-dependent fashion pointing toward an optimal therapeutic window for dasatinib dosage during polymicrobial sepsis. Dasatinib treatment may, therefore, provide a balanced immune response by preventing an overshooting inflammatory reaction on the one side and bacterial overgrowth on the other side.
- 30 April 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 901
Open AccessThe Yin and Yang of Tyrosine Kinase Inhibition During Experimental Polymicrobial Sepsis
Neutrophils are the first cells of our immune system to arrive at the site of inflammation. They release cytokines, e.g., chemokines, to attract further immune cells, but also actively start to phagocytose and kill pathogens. In the case of sepsis, this tightly regulated host defense mechanism can become uncontrolled and hyperactive resulting in severe organ damage. Currently, no effective therapy is available to fight sepsis; therefore, novel treatment targets that could prevent excessive inflammatory responses are warranted. Src Family tyrosine Kinases (SFK), a group of tyrosine kinases, have been shown to play a major role in regulating immune cell recruitment and host defense. Leukocytes with SFK depletion display severe spreading and migration defects along with reduced cytokine production. Thus, we investigated the effects of dasatinib, a tyrosine kinase inhibitor, with a strong inhibitory capacity on SFKs during sterile inflammation and polymicrobial sepsis in mice. We found that dasatinib-treated mice displayed diminished leukocyte adhesion and extravasation in tumor necrosis factor-α-stimulated cremaster muscle venules in vivo. In polymicrobial sepsis, sepsis severity, organ damage, and clinical outcome improved in a dose-dependent fashion pointing toward an optimal therapeutic window for dasatinib dosage during polymicrobial sepsis. Dasatinib treatment may, therefore, provide a balanced immune response by preventing an overshooting inflammatory reaction on the one side and bacterial overgrowth on the other side.
- Open Access
- 1 March 2006
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 16 (1) , 73-76
Atividade antioxidante e antimicrobiana de Calceolaria chelidonioides Humb. Bonpl. & Kunth.
- 1 March 2006
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 16 (1) , 73-76
Open AccessAtividade antioxidante e antimicrobiana de Calceolaria chelidonioides Humb. Bonpl. & Kunth.